This $680,594 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports novel research on the TEAD transcription factor and its interactions with the VGLL3 protein. The key objectives of this 5-year project, which runs from April 2025 to March 2030, are to: 1) Characterize the structure and functions of the TEAD-VGLL3 complex, 2) Investigate how the TEAD-VGLL3 complex confers resistance to TEAD inhibitors, and 3) Develop new TEAD inhibitors that can block the TEAD-VGLL3 interaction. This research is being conducted by the Research Management Division of The General Hospital Corporation, which does business as Massachusetts General Hospital (MGH), a leading academic medical center. The findings from this project are expected to provide important insights into the regulation and functions of the TEAD-VGLL complex, which plays critical roles in development, immune regulation, and tumorigenesis.
Generated 3/25/25, 3:28 AM